• If you are wondering whether Medtronic at around US$97.03 is offering fair value or a potential mismatch between price and worth, you are not alone.
• The stock is roughly flat over the past week with a 0.6% decline, slightly softer over the last month with a 3.6% decline, but still shows a 1.0% year to date return and 10.3% over 1 year, while the 3 year return sits at 30.1% and the 5 year return at a 2.2% decline.
• Recent attention on Medtronic has focused on its position in medical devices and how investors weigh long term demand for its products against ongoing market risks. This mix of cautious short term price moves and renewed interest in established healthcare names forms the backdrop for assessing what the current share price really reflects.
• Our model assigns Medtronic a valuation score of 3 out of 6, based on how many checks suggest the stock may be undervalued. Next we will walk through the different valuation approaches behind that number, before finishing with a broader way to think about Medtronic's worth beyond a single score.

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash Medtronic could generate in the future and discounts those back into today’s dollars, to see what that stream of cash might be worth right now.

For Medtronic, the latest twelve month free cash flow is about $5.44b. Analysts have provided free cash flow estimates for the next few years, and Simply Wall St extends those projections further. By 2028, free cash flow is projected at $7.12b, with a series of annual forecasts running out to 2035 using a 2 Stage Free Cash Flow to Equity approach.

When all those future cash flows are discounted back to today and added up, the model arrives at an estimated intrinsic value of about $94.96 per share. Against a recent share price of roughly $97.03, that implies Medtronic is about 2.2% overvalued, which is a very small gap and well within the sort of margin of error common in valuation work.

Result: ABOUT RIGHT

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Medtronic Price vs Earnings

For a profitable company like Medtronic, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of current earnings. It links directly to what you see on the income statement and is widely used across markets, which makes comparisons easier.

What counts as a “normal” P/E depends a lot on how quickly earnings are expected to grow and how risky those earnings appear. Higher growth and lower perceived risk often support a higher P/E, while slower growth or higher uncertainty tend to point to a lower one.

Medtronic currently trades on a P/E of 27.01x. That sits below the average of its immediate peers at 44.60x and also below the Medical Equipment industry average of about 30.88x. Simply Wall St’s Fair Ratio for Medtronic is 36.14x, which is its proprietary estimate of an appropriate P/E given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it incorporates these company level drivers rather than just comparing with broad groups, the Fair Ratio can provide a more tailored anchor than simple peer or industry averages.

On this basis, Medtronic’s current P/E of 27.01x is below the Fair Ratio of 36.14x.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Medtronic Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply the stories investors tell about a company and then tie directly to their own numbers for fair value, future revenue, earnings and margins. On Simply Wall St, Narratives are an easy tool on the Medtronic Community page that link your view of the business to a forecast and then to a fair value, so you can compare that fair value with the current price and decide whether the stock looks appealing or expensive based on your own assumptions. These Narratives update automatically when new information comes in, such as earnings reports or important news, so your story and valuation do not sit still. For Medtronic right now, one Narrative on the Community page assumes a fair value around US$82.66 while another puts fair value closer to US$119.43. This highlights how different investors, using the same company but different stories and assumptions, can reach very different views on what the shares are worth.

For Medtronic, however, we will make it really easy for you with previews of two leading Medtronic Narratives:

Fair value in this bullish Narrative: US$111.77 per share

Implied discount to that fair value at US$97.03: about 13% below the Narrative fair value

Revenue growth assumption: 5.89% a year

• Assumes steady demand for devices tied to chronic disease, with Medtronic using new launches in areas such as cardiac ablation, diabetes technology and hypertension management to support higher revenue.
• Builds in gradually higher profit margins as restructuring, product mix and the planned Diabetes separation are expected to support a higher earnings base over time.
• Relies on successful execution of a broad product pipeline, while noting that delays, margin pressure or a bumpy Diabetes spin off could make those earnings and valuation targets harder to reach.

Fair value in this more cautious Narrative: US$95.00 per share

Implied premium to that fair value at US$97.03: about 2.1% above the Narrative fair value

Revenue growth assumption: 5.15% a year

• Highlights Medtronic's breadth across four segments, global footprint and R&D spend as supports for the business, but questions how much of that strength is already reflected in the share price.
• Points to pressure in the Diabetes segment, tight competition in areas such as electrophysiology and glucose monitoring, and ongoing recall and regulatory risks as reasons to be careful about paying up.
• Raises the possibility that heavy spending on areas such as robotics, AI linked tools and diabetes technology may not translate into the earnings power some investors expect, especially if adoption is slower or pricing remains tight.

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.